Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1986-07-25
1988-04-12
Hollrah, Glennon H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546149, 558410, 564366, A61K 3147, C07D21720
Patent
active
047375043
ABSTRACT:
The present invention relates to novel 5-fluoro- and 8-fluoro-trimetoquinol compounds of the general formula I wherein X.sub.1 =F,X.sub.2 =H or X.sub.1 =H,X.sub.2 =F ##STR1## The present invention also relates to a process for making the 5-fluoro- and 8-fluoro-trimetoquinol compounds by condensation of an appropriately substituted phenethylamine to afford an appropriately substituted phenethylacetamide compound. The amides are cyclized to give appropriately substituted intermediate dihydroisoquinolines. Without isolation, the dihydroisoquinolines are reduced to give appropriately substituted tetrahydroisoqinolines. The hydrochloride salts of tetrahydroisoqinolines are prepared and subjected to hydrogenolysis, to give the fluorine substituted trimetoquinol compounds of the present invention. The present invention also encompasses the preparation of the phenethylamines by reducing appropriately substituted benzylcyanides and to the preparation of an intermediate benzylcyanide compound by converting a fluorine substituted methoxyphenol compound, under aminomethylation conditions into a N, N-dimethyl-4-hydroxy-3-methoxy-5-fluorobenzylamine. The benzylamine is converted to benzylnitrile and a functional group shuffle is carried out which yields the appropriately substituted benzylcyanide compound. In a composition aspect, the present invention encompasses novel pharmaceutical compositions comprising a compound of the formula I, together with a physiologically acceptable carrier or excipient, in an amount sufficient to increase .beta..sub.2 -adrenergic and antithrombotic activities while simultaneously decreasing the .beta..sub.1 -adrenergic activity in mammals, including humans. The compounds of the invention are useful in the treatment of pulmonary, cardiovascular or thromboembolic disorders.
REFERENCES:
Yamada, et al., "Chemical Abstracts", vol. 96, 1982, col. 96:85389p.
Clark, et al., "Chemical Abstracts", vol. 106, 1987, col. 106:49995z.
Kirk et al., J. Med. Chem., 22, 1493 (1979).
Miller et al., J. Med. Chem., 19:763-766 (1976).
Osei-Gyimah et al., J. Med. Chem., 21:1173-1178 (1978).
Piascik et al., Biochem. Pharmacol., 28:1807-1810 (1979).
Piascik et al., Life Sci., 24:2433-2440 (1979).
Mukhopadhyay et al., Eur. J. Pharmacol., 77:209-211 (1982).
Mukhopadhyay et al., J. Pharmacol. Exp., 231:1-9 (1985).
Kirk et al., Science, 204, 1217 (1979).
Kirk-Othmer: Encyclopedia of Chemical Technology, vol. 2, Third Edition, copyright 1978 by John Wiley & Sons, Inc.
Adejare Adeboye
Clark Michael T.
Feller Dennis R.
Miller Duane D.
Romstedt Karl J.
Hollrah Glennon H.
Ohio State University Research Foundation
Turnipseed James H.
LandOfFree
5-fluoro-and 8-fluoro-trimetoquinol compounds and the processes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-fluoro-and 8-fluoro-trimetoquinol compounds and the processes , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-fluoro-and 8-fluoro-trimetoquinol compounds and the processes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1429565